Technical Analysis for GLTO - Galecto, Inc.

Grade Last Price % Change Price Change
grade F 15.85 -0.94% -0.15
GLTO closed down 0.94 percent on Friday, November 27, 2020, on 36 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical GLTO trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Down 3 Days in a Row Weakness 0.00%
Hot IPO Pullback Bullish Swing Setup -0.94%
New 52 Week Closing High Bullish -5.88%
Pocket Pivot Bullish Swing Setup -5.88%
New 52 Week High Strength -5.88%
Hot IPO Pullback Bullish Swing Setup -1.74%
Narrow Range Bar Range Contraction -1.74%
NR7 Range Contraction -1.74%
Older End-of-Day Signals for GLTO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below 20 DMA 2 days ago
Up 3% 3 days ago
Rose Above 10 DMA 3 days ago
20 DMA Support 3 days ago
10 DMA Resistance 3 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Biotechnology Cancer Clinical Medicine Biology Inflammation Non Alcoholic Fatty Liver Disease Idiopathic Pulmonary Fibrosis Fibrosis Breakthrough Therapy Lectins Mtor Myelofibrosis Galectin 3 Pulmonary Fibrosis Galecto Biotech Related Diseases

Is GLTO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.99
52 Week Low 13.32
Average Volume 69,968
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 15.84
10-Day Moving Average 16.34
Average True Range 1.20
ADX 0.0
+DI 19.60
-DI 10.80
Chandelier Exit (Long, 3 ATRs ) 14.40
Chandelier Exit (Short, 3 ATRs ) 16.91
Upper Bollinger Band 17.28
Lower Bollinger Band 14.40
Percent B (%b) 0.5
BandWidth 18.15
MACD Line 0.25
MACD Signal Line 0.25
MACD Histogram 0.0077
Fundamentals Value
Market Cap 389.68 Million
Num Shares 24.6 Million
EPS
Price-to-Sales 0.00
Price-to-Book 11.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.14
Resistance 3 (R3) 17.25 16.93 16.93
Resistance 2 (R2) 16.93 16.60 16.88 16.85
Resistance 1 (R1) 16.39 16.40 16.23 16.28 16.78
Pivot Point 16.07 16.07 15.99 16.02 16.07
Support 1 (S1) 15.53 15.74 15.37 15.42 14.92
Support 2 (S2) 15.21 15.54 15.16 14.85
Support 3 (S3) 14.67 15.21 14.78
Support 4 (S4) 14.56